Literature DB >> 35508809

The immunology of multiple sclerosis.

Kathrine E Attfield1, Lise Torp Jensen2, Max Kaufmann3, Manuel A Friese3, Lars Fugger4,5.   

Abstract

Our incomplete understanding of the causes and pathways involved in the onset and progression of multiple sclerosis (MS) limits our ability to effectively treat this complex neurological disease. Recent studies explore the role of immune cells at different stages of MS and how they interact with cells of the central nervous system (CNS). The findings presented here begin to question the exclusivity of an antigen-specific cause and highlight how seemingly distinct immune cell types can share common functions that drive disease. Innovative techniques further expose new disease-associated immune cell populations and reinforce how environmental context is critical to their phenotype and subsequent role in disease. Importantly, the differentiation of immune cells into a pathogenic state is potentially reversible through therapeutic manipulation. As such, understanding the mechanisms that provide plasticity to causal cell types is likely key to uncoupling these disease processes and may identify novel therapeutic targets that replace the need for cell ablation.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35508809     DOI: 10.1038/s41577-022-00718-z

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  237 in total

Review 1.  Lifestyle and Environmental Factors in Multiple Sclerosis.

Authors:  Lars Alfredsson; Tomas Olsson
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 2.  Advancing the use of genome-wide association studies for drug repurposing.

Authors:  William R Reay; Murray J Cairns
Journal:  Nat Rev Genet       Date:  2021-07-23       Impact factor: 53.242

Review 3.  Neurofilaments as biomarkers in neurological disorders.

Authors:  Michael Khalil; Charlotte E Teunissen; Markus Otto; Fredrik Piehl; Maria Pia Sormani; Thomas Gattringer; Christian Barro; Ludwig Kappos; Manuel Comabella; Franz Fazekas; Axel Petzold; Kaj Blennow; Henrik Zetterberg; Jens Kuhle
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

4.  Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex.

Authors:  D Carassiti; D R Altmann; N Petrova; B Pakkenberg; F Scaravilli; K Schmierer
Journal:  Neuropathol Appl Neurobiol       Date:  2017-06-01       Impact factor: 8.090

5.  Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Authors:  Kjetil Bjornevik; Marianna Cortese; Kassandra L Munger; Alberto Ascherio; Brian C Healy; Jens Kuhle; Michael J Mina; Yumei Leng; Stephen J Elledge; David W Niebuhr; Ann I Scher
Journal:  Science       Date:  2022-01-13       Impact factor: 63.714

6.  The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Authors:  Antonio Scalfari; Chiara Romualdi; Richard S Nicholas; Miriam Mattoscio; Roberta Magliozzi; Aldo Morra; Salvatore Monaco; Paolo A Muraro; Massimiliano Calabrese
Journal:  Neurology       Date:  2018-05-16       Impact factor: 9.910

Review 7.  Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis.

Authors:  Caren Ramien; Aline Taenzer; Andreea Lupu; Nina Heckmann; Jan Broder Engler; Kostas Patas; Manuel A Friese; Stefan M Gold
Journal:  Neurosci Biobehav Rev       Date:  2016-01-08       Impact factor: 8.989

8.  TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.

Authors:  Adam P Gregory; Calliope A Dendrou; Kathrine E Attfield; Aiden Haghikia; Dionysia K Xifara; Falk Butter; Gereon Poschmann; Gurman Kaur; Lydia Lambert; Oliver A Leach; Simone Prömel; Divya Punwani; James H Felce; Simon J Davis; Ralf Gold; Finn C Nielsen; Richard M Siegel; Matthias Mann; John I Bell; Gil McVean; Lars Fugger
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

9.  Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.

Authors:  Emily A King; J Wade Davis; Jacob F Degner
Journal:  PLoS Genet       Date:  2019-12-12       Impact factor: 5.917

10.  Gene-Environment Interactions in Multiple Sclerosis: A UK Biobank Study.

Authors:  Benjamin Meir Jacobs; Alastair J Noyce; Jonathan Bestwick; Daniel Belete; Gavin Giovannoni; Ruth Dobson
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-28
View more
  7 in total

1.  Neuronal Adenosine A1 Receptor is Critical for Olfactory Function but Unable to Attenuate Olfactory Dysfunction in Neuroinflammation.

Authors:  Charlotte Schubert; Kristina Schulz; Simone Träger; Anna-Lena Plath; Asina Omriouate; Sina C Rosenkranz; Fabio Morellini; Manuel A Friese; Daniela Hirnet
Journal:  Front Cell Neurosci       Date:  2022-06-30       Impact factor: 6.147

Review 2.  RNA modifications: importance in immune cell biology and related diseases.

Authors:  Lian Cui; Rui Ma; Jiangluyi Cai; Chunyuan Guo; Zeyu Chen; Lingling Yao; Yuanyuan Wang; Rui Fan; Xin Wang; Yuling Shi
Journal:  Signal Transduct Target Ther       Date:  2022-09-22

Review 3.  Neuro-immune interactions at single-cell resolution in neurodevelopmental, infectious, and neurodegenerative diseases.

Authors:  Hyun Jung Park; Hosung Jung
Journal:  Anim Cells Syst (Seoul)       Date:  2022-08-11       Impact factor: 2.398

Review 4.  Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.

Authors:  Zheng Zha; Sisi Liu; Yijiang Liu; Chen Li; Lei Wang
Journal:  Antioxidants (Basel)       Date:  2022-07-29

5.  Impact of Multiple Sclerosis Risk Polymorphism rs7665090 on MANBA Activity, Lysosomal Endocytosis, and Lymphocyte Activation.

Authors:  Adela González-Jiménez; Pilar López-Cotarelo; Teresa Agudo-Jiménez; Ignacio Casanova; Carlos López de Silanes; Ángeles Martín-Requero; Fuencisla Matesanz; Elena Urcelay; Laura Espino-Paisán
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

6.  Mendelian randomization analysis of the causal association of bone mineral density and fracture with multiple sclerosis.

Authors:  Yu Yao; Feng Gao; Yanni Wu; Xin Zhang; Jun Xu; Haiyang Du; Xintao Wang
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

Review 7.  Antibody-mediated cell depletion therapies in multiple sclerosis.

Authors:  Alice Mariottini; Paolo A Muraro; Jan D Lünemann
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.